Posts Tagged ‘hormone-refractory’

URO TODAY: A combination of docetaxel/zoledronic/prednisone in chemotherapy for hormone refractory prostate cancer patients is safe and effective, say Indian researchers. For patients with a Gleason score less than 7, PSA declined more than 50% and those who received more than four cycles had significantly better survival. READ MORE>

Read Full Post »

URO TODAY: Docetaxel plus estramustine chemotherapy represents an active and well-tolerated treatment for Japanese hormone-refractory prostate cancer patients. READ MORE>

Read Full Post »

JULY 27: PUB MED: A trial involving men with hormone-refractory (advanced) prostate cancer who were¬† treated with Provenge (a cellular immunotherapy product called Sipuleucel-T) had a “survival benefit” and only modest side effects, say the Washington researchers. READ MORE>

The integrated results…demonstrate a survival benefit for patients treated with sipuleucel-T compared with those treated with placebo.

The generally modest toxicity profile, coupled with the survival benefit, suggests a favorable risk-benefit ratio for sipuleucel-T in patients with advanced prostate cancer.

The most common adverse events associated with treatment were chills, pyrexia (fever), headache, asthenia (physical weakness), dyspnea (shortness of breath), vomiting, and tremor.

Read Full Post »